(-)-(1R,2R,4S)-2-phenylthio-8-p-menthen-1-ol | 887611-97-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: (-)-(1R,2R,4S)-2-phenylthio-8-p-menthen-1-ol
• 英文别名: (-)-(1R,2R,5S)-2-phenylthio-8-p-methen-1-ol；(1R,2R,4S)-1-methyl-2-phenylsulfanyl-4-prop-1-en-2-ylcyclohexan-1-ol
• CAS: 887611-97-4
• 化学式: C₁₆H₂₂OS
• 分子量: 262.416
• InChiKey: PFXLAQKLXUVOTO-NUEKZKHPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  45.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (-)-(1R,2R,4S)-2-phenylthio-8-p-menthen-1-ol 在 Oxone 作用下， 以 甲醇 、 水 为溶剂， 反应 2.5h， 生成 (1R,2R,4S)-1-hydroxy-8-p-menthen-2-phenylsulfoxide
  参考文献：
  名称：

  WO2006/53766

  摘要：

  公开号：
• 作为产物：
  描述：

  苯硫酚 、 (−)-氧化柠檬烯（顺反异构体混合物） 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 19.0h， 生成 (-)-(1R,2R,4S)-2-phenylthio-8-p-menthen-1-ol 、 (1S,4S)-1-methyl-4-prop-1-en-2-yl-7-oxabicyclo[4.1.0]heptane
  参考文献：
  名称：

  WO2006/133941

  摘要：

  公开号：

文献信息

• Cannabinoid active pharmaceutical ingredient for improved dosage forms
  申请人：Kupper J. Robert

  公开号：US20070072939A1

  公开（公告）日：2007-03-29

  Pharmaceutical compositions comprising the cannabinoid active pharmaceutical ingredient, crystalline trans-(±)-Δ 9 -tetrahydrocannabinol, and formulations thereof are disclosed. The invention also relates to methods for treating or preventing a condition such as pain comprising administering to a patient in need thereof an effective amount of crystalline trans-(±)-Δ 9 -tetrahydrocannabinol. In specific embodiments, the crystalline trans-(±)-Δ 9 -tetrahydrocannabinol administered according to the methods for treating or preventing a condition such as pain can have a purity of at least about 98% based on the total weight of cannabinoids.

  本发明揭示了含有大麻活性药物成分晶态转化物-(±)-Δ9-四氢大麻酚及其制剂的制药组合物。本发明还涉及一种治疗或预防疼痛等病症的方法，包括向需要治疗的患者投与有效量的晶态转化物-(±)-Δ9-四氢大麻酚。在具体实施例中，根据治疗或预防疼痛等病症的方法投与的晶态转化物-(±)-Δ9-四氢大麻酚，其纯度可以基于大麻素的总重量而至少达到约98%。
• Methods For Purifying Trans-(-) Delta9-Tetrahydrocannabinol And Trans-(+)-Delta9-Tetrahydrocannabinol
  申请人：Gutman Arie L.

  公开号：US20090298930A1

  公开（公告）日：2009-12-03

  Methods for making trans-(−)-Δ 9 -tetrahydrocannabinol and trans-(+)-Δ 9 -tetrahydrocannabinol are disclosed herein. In one embodiment, a trans-(−)-Δ 9 -tetrahydrocannabinol composition is prepared by allowing a composition comprising (±)-Δ 9 -tetrahydrocannabinol to separate on a chiral stationary phase to provide a trans-(−)-Δ 9 -tetrahydrocannabinol composition comprising at least about 99% by weight of trans-(−)-Δ 9 -tetrahydrocannabinol based on the total amount of trans-(−)-Δ 9 -tetrahydrocannabinol and trans-(+)-Δ 9 -tetrahydrocannabinol. The invention also relates to methods for treating or preventing a condition such as pain comprising administering to a patient in need thereof an effective amount of a trans-(−)-Δ 9 -tetrahydrocannabinol having a purity of at least about 98% based on the total weight of cannabinoids.

  本文披露了制备反式-(−)-Δ9-四氢大麻酚和反式-(+)-Δ9-四氢大麻酚的方法。在一种实施方式中，通过让包含(±)-Δ9-四氢大麻酚的组合物在手性固定相上分离，制备了一种反式-(−)-Δ9-四氢大麻酚组合物，其中反式-(−)-Δ9-四氢大麻酚的重量占反式-(−)-Δ9-四氢大麻酚和反式-(+)-Δ9-四氢大麻酚总量的至少约99%。本发明还涉及治疗或预防疼痛等病症的方法，包括向需要的患者施用至少98%纯度的反式-(−)-Δ9-四氢大麻酚的有效剂量，基于大麻素的总重量。
• METHODS FOR PURIFYING TRANS-(-)-DELTA9-TETRAHYDROCANNABINOL AND TRANS-(+)-DELTA9-TETRAHYDROCANNABINOL
  申请人：Purdue Pharma L.P.

  公开号：US20130171259A1

  公开（公告）日：2013-07-04

  Methods for making trans-(−)-Δ 9 -tetrahydrocannabinol and trans-(+)-Δ 9 -tetrahydrocannabinol are disclosed herein. In one embodiment, a trans-(−)-Δ 9 -tetrahydrocannabinol composition is prepared by allowing a composition comprising (±)-Δ 9 )-tetrahydrocannabinol to separate on a chiral stationary phase to provide a trans-(−)-Δ 9 -tetrahydrocannabinol composition comprising at least about 99% by weight of trans-(−)-Δ 9 -tetrahydrocannabinol based on the total amount of trans-(−)-Δ 9 -tetrahydrocannabinol and trans-(+)-Δ 9 -tetrahydrocannabinol. The invention also relates to methods for treating or preventing a condition such as pain comprising administering to a patient in need thereof an effective amount of a trans-(−)-Δ 9 -tetrahydrocannabinol having a purity of at least about 98% based on the total weight of cannabinoids.

  本文公开了制备反式-(−)-Δ9-四氢大麻酚和反式-(+)-Δ9-四氢大麻酚的方法。在一种实施例中，通过让包含(±)-Δ9-四氢大麻酚的组成物在手性固定相上分离，制备出反式-(−)-Δ9-四氢大麻酚组成物，其中反式-(−)-Δ9-四氢大麻酚的重量占反式-(−)-Δ9-四氢大麻酚和反式-(+)-Δ9-四氢大麻酚总量的至少约99%。本发明还涉及治疗或预防疼痛等疾病的方法，包括向需要治疗的患者投与至少约98%纯度的反式-(−)-Δ9-四氢大麻酚，其基于大麻素总重量计算。
• METHODS FOR PURIFYING TRANS-(-)-Delta9-TETRAHYDROCANNABINOL AND TRANS-(+)-Delta9-TETRAHYDROCANNABINOL
  申请人：SVC Pharma LP

  公开号：US20150126596A1

  公开（公告）日：2015-05-07

  Methods for making trans-(−)-Δ 9 -tetrahydrocannabinoI and trans-(+)-Δ 9 -tetrahydrocannabinol are disclosed herein. In one embodiment, a trans-(−)-Δ 9 -tetrahydrocannabinoI composition is prepared by allowing a composition comprising (±)-Δ 9 -tetrahydrocannabinol to separate on a chiral stationary phase to provide a trans-(−)-Δ 9 -tetrahydrocannabinoI composition comprising at least about 99% by weight of trans-(−)-Δ 9 -tetrahydrocannabinol based on the total amount of trans-(−)-Δ 9 -tetrahydrocannabinol and trans-(+)-Δ 9 -tetrahydrocannabinol. The invention also relates to methods for treating or preventing a condition such as pain comprising administering to a patient in need thereof an effective amount of a trans-(−)-Δ 9 -tetrahydrocannabinoI having a purity of at least about 98% based on the total weight of cannabinoids.

  本文披露了制备反式-(−)-Δ9-四氢大麻酚和反式-(+)-Δ9-四氢大麻酚的方法。在一种实施例中，通过让包含(±)-Δ9-四氢大麻酚的组合物在手性固定相上分离，制备出含有至少约99%按重量计的反式-(−)-Δ9-四氢大麻酚的组合物，基于反式-(−)-Δ9-四氢大麻酚和反式-(+)-Δ9-四氢大麻酚的总量。本发明还涉及用含有至少约98%按重量计的大麻素总量的反式-(−)-Δ9-四氢大麻酚的有效量，治疗或预防疼痛等病症的方法。
• METHODS FOR PURIFYING TRANS-(-)-Δ9-TETRAHYDROCANNABINOL AND TRANS-(+)-Δ9 TETRAHYDROCANNABINOL
  申请人：SVC Pharma LP

  公开号：US20160199344A1

  公开（公告）日：2016-07-14

  Methods for making trans-(−)-Δ 9 -tetrahydrocannabinol and trans-(+)-Δ 9 -tetrahydrocannabinol are disclosed herein. In one embodiment, a trans-(−)-Δ 9 -tetrahydrocannabinol composition is prepared by allowing a composition comprising (±)-Δ 9 -tetrahydrocannabinol to separate on a chiral stationary phase to provide a trans-(−)-Δ 9 -tetrahydrocannabinol composition comprising at least about 99% by weight of trans-(−)-Δ 9 -tetrahydrocannabinol based on the total amount of trans-(−)-Δ 9 -tetrahydrocannabinol and trans-(+)-Δ 9 -tetrahydrocannabinol. The invention also relates to methods for treating or preventing a condition such as pain comprising administering to a patient in need thereof an effective amount of a trans-(−)-Δ 9 -tetrahydrocannabinol having a purity of at least about 98% based on the total weight of cannabinoids.

  本文披露了制备反式（-）- Δ9-四氢大麻酚和反式（+）- Δ9-四氢大麻酚的方法。在一种实施例中，通过让包含（±）- Δ9-四氢大麻酚的组合物在手性固定相上分离，制备了反式（-）- Δ9-四氢大麻酚组合物，其中反式（-）- Δ9-四氢大麻酚的重量占反式（-）- Δ9-四氢大麻酚和反式（+）- Δ9-四氢大麻酚总量的至少约99％。本发明还涉及治疗或预防疼痛等症状的方法，包括向需要治疗的患者施用至少约98％的纯度的反式（-）- Δ9-四氢大麻酚的有效量，基于大麻素的总重量。